Background: Despite the widespread use of highly active antiretroviral therapy, HIV-associated neurocognitive disorders (HAND) remain prevalent and may be associated with cumulative exposure to antiretroviral (ARV) medications and other factors. We proposed that chronic toxic effects of ARV drugs on the blood vessel walls could contribute to cerebral small vessel disease (CSVD), which even at its early stages could lead to disturbance of cerebrovascular autoregulation and deficiency in functional hyperemia. Methodology: We assembled 144 consecutive autopsy HIV-infected cases that had detailed data on ARV medications ever used during the entire period of follow-up observation and died during 1999−2011. In studying associations between the use of ARV drugs and the occurrence of blood vessel pathology in the brain, we included three major drug classes: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). We employed multinomial logistic regression to determine associations between the use of ARV drugs and the occurrence of CSVD. Forebrain CSVD was defined as concentric intramural hyalinization of small arteries or arterioles in the forebrain leptomeninges and parenchyma. CSVD was graded as absent, mild, or severe. Results: Mild CSVD was present in 24.8% and severe CSVD in 47.4% of 137 cases. On multinomial logistic regression analysis, the use of NRTIs or PIs was associated with the higher odds of mild CSVD (relative to absent) [OR 19.23 and 2.84, P=0.003 and =0.06, respectively]. No association was found between mild CSVD and any of the potential covariates. In contrast, the occurrence of severe CSVD (relative to absent) was associated with older age or diabetes (OR 2.56 and 6.55, P=0.035 and =0.01, respectively), but not with any of the ARV-related predictors. Notably, HAND was associated with mild CSVD (OR 4.82). No other significant associations between pathologic changes and HAND were found. Conclusions: The clinical importance of mild CSVD in our study was substantiated by the finding that mild CSVD was predictive of HAND. Our findings suggest that the use of NRTIs or PIs may increase the risk of mild CSVD and consequently neurocognitive impairment. Interestingly, we found no significant association between the use of any ARV drug classes during life and the presence of HIV encephalitis at autopsy. Although our study analyzed the adverse effects of individual major ARV drug classes, different ARV drugs even in the same class might carry differential degrees of toxicity on cerebral vessels. We are pursuing now studies of the molecular mechanisms of ARV toxicity to the cell components of cerebral vessels and identification of potential biomarkers for CSVD in HIV-infected patients.